Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 17.83M -68.5% |
| Revenue (ttm) | 1.89M -16.0% |
| Net Income | -29.65M |
| EPS | -29.93 |
| Shares Out | 2.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,954 |
| Average Volume | 8,309 |
| Open | 670.00 |
| Previous Close | 677.40 |
| Day's Range | 670.00 - 712.00 |
| 52-Week Range | 560.00 - 8,100.00 |
| Beta | -0.50 |
| RSI | 26.42 |
| Earnings Date | Mar 27, 2026 |
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treat... [Read more]
Financial Performance
In 2024, Can-Fite BioPharma's revenue was $674,000, a decrease of -9.29% compared to the previous year's $743,000. Losses were -$7.88 million, 3.22% more than in 2023.
Financial numbers in USD Financial StatementsNews
Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results
Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results
Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson
Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson
Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant
Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant
Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial
Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial
Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split
Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split
Can-Fite BioPharma (CANF) Announces Significant Reverse Split
Can-Fite BioPharma (CANF) Announces Significant Reverse Split
Can-Fite BioPharma approves 1-for-3,000 reverse share split; shares down
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
RAMAT GAN, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs target...
CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News
CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News
CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position
CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position
Can-Fite Provides Update on Clinical and Financial Status
RAMAT GAN, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs target...
Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025
Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025
Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment
Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment
Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
~35% of erectile dysfunction patients in a $3.2 billion market are non-responders to brands including Viagra and Cialis, and these drugs can be contraindicated for an estimated 16 million men living w...
CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News
CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News
Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival
Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival
CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News
CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News
CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News
CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News
Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment
Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment
Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.2M
Can-Fite Reports H1 2025 Financial Results and Clinical Update
Ramat Gan, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targe...
Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone
Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CA...
Can-Fite Announces Up To $15.0 Million Public Offering
$5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia
Ramat Gan, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molec...